AI-generated summary
The authors randomized patients with pemphigus vulgaris oral lesions, all also receiving systemic prednisone, to a 645 nm diode laser or sham treatment. They report a significant pain score (VAS) reduction in both groups at 4 and 8 weeks, and a lesion size difference between groups only at 8 weeks. The authors describe the therapy as a possible supportive option and call for larger trials.
- Who or what was studied
- Patients with pemphigus vulgaris induced erosive-ulcerative oral lesions, also receiving systemic prednisone; 50 lesions were evaluated
- Wavelengths
- 645 nm
- Limits stated in the abstract
- The abstract states that larger randomized trials with wide sample sizes and standardized protocols are suggested.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on pubmed.ncbi.nlm.nih.gov.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 645 nm
- Energy density (fluence)
- 3 J/cm2
- Power
- 100 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Photobiomodulation, Photobiomodulation therapy, Visual analogue scale, Placebo-controlled, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.